Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.
This anti-diabetic drug used for weight loss has been approved by US FDA: When will India see its launch?
The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in obese adults. Developed by Eli Lilly, this drug offers an alternative to traditional breathing devices,
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.
Popular Weight Loss Drug Zepbound Gains FDA Approval to Treat Sleep Apnea
The FDA has approved Eli Lilly's Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity.
Weight loss drug Zepbound gets US FDA nod to treat sleep apnea; India launch expected in 2025
In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known as Tirzepatide, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
This Popular Weight Loss Drug Can Now Be Used To Treat Sleep Apnea
Zepbound is the first medication approved to treat people with obstructive sleep apnea, said Sailly Seymor, director of FDA's division of pulmonology, allergy, and critical care.
FDA Approves Zepbound for Obstructive Sleep Apnea
FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
News Nation on MSN16h
Eggs added to FDA’s updated healthy claim food list
The Food and Drug Administration has added eggs to its updated list of healthy foods along with fish and vegetables ...
McKnight's Long-Term Care News1d
FDA updates meaning of ‘healthy’ on food labels
The US Food and Drug Administration wants to redefine the meaning of healthy food, issuing a new rule Thursday that changes ...
FDA approves anti-obesity drug as first sleep apnea medication
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...
Merck to discontinue drug for bacterial infection
Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug ...
FDA says shortage of GLP-1 drug tirzepatide is over
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
Eggs now qualify as ‘healthy’ food, FDA says: Here’s why
While eggs haven’t historically been considered a "health food," the U.S. Food and Drug Administration (FDA) now classifies ...
US FDA approves Hikma's generic version of Novo's diabetes drug Victoza
The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...
Medscape1d
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
Peninsula drugmaker lands $150 million, food allergy drug to fill pipeline hole
If your drug trials don't succeed, try again with another drug — and raise more money. That's $RAPT's plan as it targets food ...